Navigation Links
New Venture Funding for Alzheimer's Disease Drug Developer
Date:1/12/2009

MADISON, Wis., Jan. 12 /PRNewswire/ -- Mithridion, Inc., a drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease (AD), announced today that it held an initial closing of $2.9 million in Series B Preferred Stock financing. The company will use the funds for the clinical development of MCD-386, its lead drug candidate, aimed at stopping or slowing down disease progression and improving memory and cognition in this devastating disorder. The company has raised $7.4 million to date in equity funding.

Venture Investors (VI - Madison, Wis.) led this latest round of financing. The State of Wisconsin Investment Board and Wisconsin Investment Partners, both of Madison, Wis., and Rocket Venture Fund (Toledo. Ohio), all existing shareholders, also participated in the latest funding. Mithridion plans to hold a final closing with respect to this financing on or before March 31, 2009.

John Neis, Managing Director of VI, will join Mithridion's board of directors.

"This new funding will enable Mithridion not only to advance MCD-386 in Phase I trial, but will also support the development of exciting drug leads for AD and schizophrenia in our preclinical pipeline," said Trevor M. Twose, Ph.D., the company's Chief Executive. "We greatly appreciate the continued support of our shareholders," he added.

Five million Americans suffer from Alzheimer's disease today, and the number will grow as baby-boomers age. The market for Alzheimer's disease drugs exceeds $4 billion, but is currently underserved, and may grow to greater than $10 billion with the development of drugs that are more effective.

MCD-386 is highly selective for the M1-type muscarinic receptor. In preclinical laboratory tests, MCD-386 appears to replace deficient brain acetylcholine activity, similar to that caused by AD. This drug is intended to improve memory and cognition, with improved tolerability compared to previously tested M1-selective muscarinic drugs. MCD-386 also appeared to activate alpha-secretase enzymes, which might reduce or prevent the loss of brain cells in AD by preventing the formation of amyloid beta. In preclinical laboratory tests, MCD-386 appeared to be superior to the best first-generation drug candidates of this type.

Four of the five currently approved drugs slow down the breakdown of acetylcholine, thereby boosting its concentration to overcome the deficiency in AD. However, unlike these drugs, MCD-386 is designed to mimic only the M1 activity of acetylcholine, with potentially greater efficacy and less side-effects.

Mithridion's headquarters and preclinical drug research laboratories are in Madison, Wis., and its semi-virtual clinical drug development team operates out of Toledo, Ohio. The Company commenced operations in February 2006. During 2008, Mithridion acquired Cognitive Pharmaceuticals Ltd., (Toledo, Ohio), raised $2.3 million of Series B funding, and successfully completed the first stage of Phase I clinical trials of MCD-386.

Venture Investors is a venture capital firm with $190 million under management. The firm invests in seed and early-stage life science and technology companies in the Midwest, with a primary focus on opportunities that spin out of the region's leading research universities. Formed in 1982, Venture Investors has offices strategically located next to the country's third and fourth largest research institutions in Ann Arbor, Mich., and Madison, Wisc. For additional information on the firm, visit www.ventureinvestors.com.


'/>"/>
SOURCE Mithridion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
2. NTU and Insightra Medical Inc. release their first joint venture medical device
3. Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
4. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
5. Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank
6. Venture Health Group Selects Planet DDS Web-based Practice Management Software
7. HLM Venture Partners Leads Series B Financing of CaseNET, Inc.
8. RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital
9. MM2 Group Establishes New Venture for Sofgel Manufacture in China
10. Radius Ventures Announces Promotion of Dr. David Stoffel to Partner
11. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased to announce its ... the Pharma Landscape .” CMS recently proposed a test of alternate payment models for ... preserving care provided to beneficiaries. The webinar will review the details of this model, ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Evolve Paddle Board Company- which specializes ... today the outcome of their partnership with Yoloha Yoga- producers of high quality cork ... , SUP yoga has seen a dramatic rise in popularity throughout the last few ...
(Date:5/2/2016)... TN (PRWEB) , ... May 02, 2016 , ... ... and behavioral health services, today announced the opening of Twin Lakes Recovery Center. ... will be Summit’s first in the state. The residential facility is set ...
(Date:5/2/2016)... CA (PRWEB) , ... May 02, 2016 , ... ... offering regenerative therapy, which includes amniotic fluid/“stem cells” and Platelet Rich Plasma (PRP) ... athletes and celebrities,” said Dr. James Baranski, D.C., of Advanced Spine & Sport ...
(Date:5/1/2016)... ... May 01, 2016 , ... Women’s Excellence ... new mothers a better understanding of what to expect after they deliver. The ... baby postpartum, · The blues and depression, · Breastfeeding beyond postpartum · Baby ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years clinical ... and biotechnology industries. His last role was at Mologen ... of the Executive Board. Previously Dr. Zurlo held various ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
(Date:4/28/2016)... April 28, 2016 Dr. Vivek ... and Ste phen Schmidt ... a leading provider of cloud-based software solutions for life sciences, today ... to bring a wealth of insight to a growing business.  This ... George Phillips joined ArisGlobal in the position ...
Breaking Medicine Technology: